The simple, 12-day differentiation protocol is performed in two stages. During the first 3 days, STEMdiff™ Hematopoietic Supplement A is added to the basal medium to induce cells toward mesoderm. For the subsequent 9 days, mesodermal cells are further differentiated into hematopoietic progenitor cells using basal medium supplemented with STEMdiff™ Hematopoietic Supplement B. At the end of the 12-day protocol, hematopoietic cells can be easily harvested from the culture supernatant. This population typically contains 25 - 65% (average 43%) CD34+CD45+ progenitor cells, including progenitor cells that have the capacity to form hematopoietic colonies in the colony-forming unit (CFU) assay.
STEMdiff™ Hematopoietic Kit has been optimized for differentiation of cells maintained in mTeSR™1 (Catalog #85850), mTeSR™ Plus(Catalog #100-0276), or TeSR™-E8™ (Catalog #05990).
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Data and Publications
Figure 1. Hematopoietic Differentiation Protocol
On Day -1, harvest and seed human ES/iPS cell colonies as small aggregates in mTeSR™1, mTeSR™ Plus, or TeSR™-E8. After one day, TeSR™ medium is replaced with Medium A (STEMdiff™ Hematopoietic Basal Medium containing Supplement A) to begin inducing the cells towards a mesoderm-like state (day 0). On day 2, a half medium change is performed with fresh Medium A. On day 3, the medium is changed to Medium B (STEMdiff™ Hematopoietic Basal Medium containing Supplement B) with half medium changes on days 5, 7 and 10, to promote further differentiation into hematopoietic cells. Typically, by day 12, large numbers of HPCs can be harvested from the culture supernatant.
Figure 2. Morphology of hPSC-Derived HPCs
Representative images of (A) hES (H1) cells and (B) hiPS (WLS-1C) cells on Day 12 of differentiation to HPCs using the STEMdiff™ Hematopoietic Kit. Differentiated cells exhibit typical HPC morphology as round cells that float freely in suspension.
Figure 3. Efficient and Robust Generation of CD34+CD45+/CD43+ HPCs
hES and hiPS cells were cultured for 12 days in single wells of 12-well plates using the STEMdiff™ Hematopoietic Kit. At the end of the culture period, cells in suspension were harvested and analyzed by flow cytometry for expression of hematopoietic cell surface markers: CD34, CD45 and CD43. (A,B) Example flow cytometry plots for hematopoietic cell surface-marker analysis of cultures of hES (H1 and H9) and hiPS (STiPS-M001) cells. (C,D) Percentages and total numbers of CD34+CD45+ cells in cultures of hES (H1 and H9) or hiPS (WLS-1C, STiPS-F016, STiPS-M001 and STiPS-B004) cells are shown. Data shown as mean ± SEM; n ≥ 3.
Figure 4. hPSC-Derived HPCs Produce Colonies of Multiple Lineages
Cells in suspension were harvested from the cultures on Day 12 of the hematopoietic differentiation protocol and assessed in colony-forming unit (CFU) assays using MethoCult™ H4435 Enriched (Catalog #04435) methylcellulose-based medium. (A) CFU frequencies in cultures of 6 different hPSC lines. (Data shown as mean ± SEM; n ≥ 3.) The CFU frequencies were variable between the different cell lines, with on average approximately 120 CFU per 10,000 hPSC-derived HPCs plated. (B) The progenitor cell types observed included granulocyte/macrophage (CFU-M, CFU-G and CFU-GM), erythroid (BFU-E and CFU-E) and occasional mixed (CFU-GEMM) colonies. Representative colony images are shown at 40X magnification.